Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies ClonoSEQ Expansion

Adaptive Biotechnologies has announced the expansion of its clonoSEQ process to include minimal residual disease analysis of cells harvested from patients with lymphoid cancers being prepared for autologous stem cell transplant. The expansion will allow physicians to prepare patients for autologous stem cell transplants by providing prognostic information that may potentially inform treatment decisions about maintenance post-transplant, Tom Willis, senior vice president and general manager of diagnostic products at Adaptive Biotechnologies, said in a statement. Physicians wishing to submit autograft samples should fill out the clonoSEQ MRD Test Requisition Form and submit samples using a clonoSEQ Specimen Kit to Adaptive's CLIA-certified, CAP-accredited laboratory in South San Francisco. Results will be available within seven days of sample receipt.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.